US FDA OK's EffRx’s effervescent osteoporosis drug
This article was originally published in Scrip
Executive Summary
Swiss firm EffRx Pharmaceuticals was granted approval by the US FDA for Binosto (alendronate sodium) as the first and only effervescent tablet to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.